Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Locally Advanced or Metastatic Chordoma
NCT06787664Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in chordoma, sponsored by Biokin Pharmaceutical. Started Jan 2025; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT06787664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787664.